Etrolizumab in moderate-to-severe ulcerative colitis

Alessandro Armuzzi; Carla Felice

doi:10.1016/S0140-6736(14)60529-8

Etrolizumab in moderate-to-severe ulcerative colitis

Alessandro Armuzzi
, Carla Felice

Università Cattolica del Sacro Cuore

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

no abstract available

Original language	English
Pages (from-to)	285-286
Number of pages	2
Journal	THE LANCET
Volume	384
DOIs	https://doi.org/10.1016/S0140-6736(14)60529-8
Publication status	Published - 2014

Keywords

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Colitis, Ulcerative
Female
Humans
Male

Access to Document

10.1016/S0140-6736(14)60529-8

Cite this

@article{8f817244dea143c5b81c3e8bca9219c7,

title = "Etrolizumab in moderate-to-severe ulcerative colitis",

abstract = "no abstract available",

keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Female, Humans, Male, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Female, Humans, Male",

author = "Alessandro Armuzzi and Carla Felice",

year = "2014",

doi = "10.1016/S0140-6736(14)60529-8",

language = "English",

volume = "384",

pages = "285--286",

journal = "THE LANCET",

issn = "0099-5355",

publisher = "The Lancet:6277 Sea Harbor:Orlando, FL 32887:(800)462-6198, EMAIL: [email protected], INTERNET: http://www.thelancet.com, Fax: (407)363-1354",

}

TY - JOUR

T1 - Etrolizumab in moderate-to-severe ulcerative colitis

AU - Armuzzi, Alessandro

AU - Felice, Carla

PY - 2014

Y1 - 2014

N2 - no abstract available

AB - no abstract available

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Colitis, Ulcerative

KW - Female

KW - Humans

KW - Male

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Colitis, Ulcerative

KW - Female

KW - Humans

KW - Male

UR - http://hdl.handle.net/10807/64544

U2 - 10.1016/S0140-6736(14)60529-8

DO - 10.1016/S0140-6736(14)60529-8

M3 - Article

SN - 0099-5355

VL - 384

SP - 285

EP - 286

JO - THE LANCET

JF - THE LANCET

ER -

Etrolizumab in moderate-to-severe ulcerative colitis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this